Plain-English translation of NCT06467097 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining standard kidney cancer medications with a specialized radiation treatment called stereotactic ablative radiotherapy (SABR) helps patients live longer without their cancer getting worse. Half of the participants will receive only the standard medications—like targeted therapy or immunotherapy drugs. The other half will receive the same medications plus focused radiation aimed at killing each cancer spot.
Doctors have noticed that high-dose radiation can slow down cancer growth and may delay the need for more treatment, but no one has proven yet whether adding this radiation to standard medications actually helps patients with kidney cancer live longer than medication alone.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of two groups. One group receives only standard cancer medications. The other group receives the same medications plus several sessions of focused radiation therapy to target each cancer spot. You will have regular visits to check your health, blood work, and scans to see how well the treatment is working. The study follows you over time to see whether adding radiation helps slow your cancer better than medication alone.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
South Korea
Phase
Large-scale testing
Sponsor
Samsung Medical Center
Enrollment target
~88 participants
Started
April 2024
Primary completion
February 2031
Age range
20 Years – 80 Years
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Won Park, M.D., Ph.D.
Samsung Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.